BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 27401816)

  • 21. Curcuminoid EF24 enhances the anti-tumour activity of Akt inhibitor MK-2206 through ROS-mediated endoplasmic reticulum stress and mitochondrial dysfunction in gastric cancer.
    Chen X; Dai X; Zou P; Chen W; Rajamanickam V; Feng C; Zhuge W; Qiu C; Ye Q; Zhang X; Liang G
    Br J Pharmacol; 2017 May; 174(10):1131-1146. PubMed ID: 28255993
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systemic administration of polymeric nanoparticle-encapsulated curcumin (NanoCurc) blocks tumor growth and metastases in preclinical models of pancreatic cancer.
    Bisht S; Mizuma M; Feldmann G; Ottenhof NA; Hong SM; Pramanik D; Chenna V; Karikari C; Sharma R; Goggins MG; Rudek MA; Ravi R; Maitra A; Maitra A
    Mol Cancer Ther; 2010 Aug; 9(8):2255-64. PubMed ID: 20647339
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NEMO peptide inhibits the growth of pancreatic ductal adenocarcinoma by blocking NF-κB activation.
    Zhuang Z; Li H; Lee H; Aguilar M; Gocho T; Ju H; Iida T; Ling J; Fu J; Wu M; Sun Y; Lu Y; Chiao PJ
    Cancer Lett; 2017 Dec; 411():44-56. PubMed ID: 28951128
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Curcumin analog EF24 induces apoptosis via ROS-dependent mitochondrial dysfunction in human colorectal cancer cells.
    He G; Feng C; Vinothkumar R; Chen W; Dai X; Chen X; Ye Q; Qiu C; Zhou H; Wang Y; Liang G; Xie Y; Wu W
    Cancer Chemother Pharmacol; 2016 Dec; 78(6):1151-1161. PubMed ID: 27787644
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of nuclear factor kappa-B enhances the antitumor effect of combination treatment with tumor necrosis factor-alpha gene therapy and gemcitabine for pancreatic cancer in mice.
    Fujiwara Y; Shiba H; Iwase R; Haruki K; Furukawa K; Uwagawa T; Misawa T; Ohashi T; Yanaga K
    J Am Coll Surg; 2013 Feb; 216(2):320-32.e3. PubMed ID: 23219147
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Piperlongumine Suppresses Growth and Sensitizes Pancreatic Tumors to Gemcitabine in a Xenograft Mouse Model by Modulating the NF-kappa B Pathway.
    Wang Y; Wu X; Zhou Y; Jiang H; Pan S; Sun B
    Cancer Prev Res (Phila); 2016 Mar; 9(3):234-44. PubMed ID: 26667450
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Shikonin suppresses tumor growth and synergizes with gemcitabine in a pancreatic cancer xenograft model: Involvement of NF-κB signaling pathway.
    Wang Y; Zhou Y; Jia G; Han B; Liu J; Teng Y; Lv J; Song Z; Li Y; Ji L; Pan S; Jiang H; Sun B
    Biochem Pharmacol; 2014 Apr; 88(3):322-33. PubMed ID: 24522113
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Arginine deiminase augments the chemosensitivity of argininosuccinate synthetase-deficient pancreatic cancer cells to gemcitabine via inhibition of NF-κB signaling.
    Liu J; Ma J; Wu Z; Li W; Zhang D; Han L; Wang F; Reindl KM; Wu E; Ma Q
    BMC Cancer; 2014 Sep; 14():686. PubMed ID: 25240403
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Concurrent inhibition of NF-kappaB, cyclooxygenase-2, and epidermal growth factor receptor leads to greater anti-tumor activity in pancreatic cancer.
    Ali S; Banerjee S; Schaffert JM; El-Rayes BF; Philip PA; Sarkar FH
    J Cell Biochem; 2010 May; 110(1):171-81. PubMed ID: 20213764
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models.
    Feldmann G; Mishra A; Bisht S; Karikari C; Garrido-Laguna I; Rasheed Z; Ottenhof NA; Dadon T; Alvarez H; Fendrich V; Rajeshkumar NV; Matsui W; Brossart P; Hidalgo M; Bannerji R; Maitra A; Nelkin BD
    Cancer Biol Ther; 2011 Oct; 12(7):598-609. PubMed ID: 21768779
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhanced antitumor efficacy by the combination of emodin and gemcitabine against human pancreatic cancer cells via downregulation of the expression of XIAP in vitro and in vivo.
    Wang ZH; Chen H; Guo HC; Tong HF; Liu JX; Wei WT; Tan W; Ni ZL; Liu HB; Lin SZ
    Int J Oncol; 2011 Nov; 39(5):1123-31. PubMed ID: 21743963
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multiple anticancer activities of EF24, a novel curcumin analog, on human ovarian carcinoma cells.
    Tan X; Sidell N; Mancini A; Huang RP; Shenming Wang ; Horowitz IR; Liotta DC; Taylor RN; Wieser F
    Reprod Sci; 2010 Oct; 17(10):931-40. PubMed ID: 20693500
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synergistic antitumor activity of rapamycin and EF24 via increasing ROS for the treatment of gastric cancer.
    Chen W; Zou P; Zhao Z; Chen X; Fan X; Vinothkumar R; Cui R; Wu F; Zhang Q; Liang G; Ji J
    Redox Biol; 2016 Dec; 10():78-89. PubMed ID: 27697670
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Escin augments the efficacy of gemcitabine through down-regulation of nuclear factor-κB and nuclear factor-κB-regulated gene products in pancreatic cancer both in vitro and in vivo.
    Wang YW; Wang SJ; Zhou YN; Pan SH; Sun B
    J Cancer Res Clin Oncol; 2012 May; 138(5):785-97. PubMed ID: 22270965
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Da0324, an inhibitor of nuclear factor-κB activation, demonstrates selective antitumor activity on human gastric cancer cells.
    Jin R; Xia Y; Chen Q; Li W; Chen D; Ye H; Zhao C; Du X; Shi D; Wu J; Liang G
    Drug Des Devel Ther; 2016; 10():979-95. PubMed ID: 27042000
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF.
    Ali S; Ahmad A; Banerjee S; Padhye S; Dominiak K; Schaffert JM; Wang Z; Philip PA; Sarkar FH
    Cancer Res; 2010 May; 70(9):3606-17. PubMed ID: 20388782
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthetic curcumin analog EF31 inhibits the growth of head and neck squamous cell carcinoma xenografts.
    Zhu S; Moore TW; Lin X; Morii N; Mancini A; Howard RB; Culver D; Arrendale RF; Reddy P; Evers TJ; Zhang H; Sica G; Chen ZG; Sun A; Fu H; Khuri FR; Shin DM; Snyder JP; Shoji M
    Integr Biol (Camb); 2012 Jun; 4(6):633-40. PubMed ID: 22532032
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New treatment strategy with nuclear factor-κB inhibitor for pancreatic cancer.
    Horiuchi T; Uwagawa T; Shirai Y; Saito N; Iwase R; Haruki K; Shiba H; Ohashi T; Yanaga K
    J Surg Res; 2016 Nov; 206(1):1-8. PubMed ID: 27916347
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nanoformulation of Apolipoprotein E3-Tagged Liposomal Nanoparticles for the co-Delivery of KRAS-siRNA and Gemcitabine for Pancreatic Cancer Treatment.
    Wang F; Zhang Z
    Pharm Res; 2020 Nov; 37(12):247. PubMed ID: 33216236
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MicroRNA-33b, upregulated by EF24, a curcumin analog, suppresses the epithelial-to-mesenchymal transition (EMT) and migratory potential of melanoma cells by targeting HMGA2.
    Zhang P; Bai H; Liu G; Wang H; Chen F; Zhang B; Zeng P; Wu C; Peng C; Huang C; Song Y; Song E
    Toxicol Lett; 2015 May; 234(3):151-61. PubMed ID: 25725129
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.